This simple guide explains how GLP-1s work, their benefits for diabetes and obesity, and their growing potential in other health conditions like heart disease, chronic kidney disease, Alzheimers, and even addiction
In March, the Group Insurance Commission, for example, approved average premium increases of 7.5 percent for thousands of public employees for fiscal year 2027
Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M: Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and-independent pathways
Y., Wong, G
Novo's semaglutide mistakes: Relied on single GLP-1 mechanism (less differentiated) Didn't manage secondary patent portfolio aggressively Face injunctions despite composition patent expiry Lilly's tirzepatide advantages: Dual mechanism (harder to design around) Vial-first strategy (captured price-sensitive patients) Strategic partnerships (Cipla for distribution) First-mover advantage in obesity positioning FOR YOUR ORGANIZATION If you're Eli Lilly/patent counsel: Mounjaro proves robust patent strategy + product differentiation can sustain premium pricing in India
[1] The proposal targets the 503B bulks list one of the legal pathways that has allowed large-scale compounding of GLP-1 medications to flow into the telehealth market over the past several years